ExpreS2ion Biotech Holding Past Earnings Performance
Past criteria checks 0/6
ExpreS2ion Biotech Holding's earnings have been declining at an average annual rate of -44.9%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 7.2% per year.
Key information
-44.9%
Earnings growth rate
-19.0%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | -7.2% |
| Return on equity | -157.5% |
| Net Margin | -1,090.9% |
| Next Earnings Update | 08 May 2024 |
Revenue & Expenses BreakdownBeta
How ExpreS2ion Biotech Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 9 | -96 | 58 | 51 |
| 30 Sep 23 | 8 | -125 | 60 | 80 |
| 30 Jun 23 | 7 | -136 | 60 | 90 |
| 31 Mar 23 | 7 | -131 | 59 | 84 |
| 31 Dec 22 | 6 | -119 | 56 | 71 |
| 30 Sep 22 | 9 | -84 | 58 | 35 |
| 30 Jun 22 | 11 | -63 | 49 | 18 |
| 31 Mar 22 | 14 | -47 | 42 | 9 |
| 31 Dec 21 | 14 | -44 | 36 | 10 |
| 30 Sep 21 | 15 | -47 | 39 | 8 |
| 30 Jun 21 | 15 | -42 | 41 | 6 |
| 31 Mar 21 | 14 | -38 | 39 | 3 |
| 31 Dec 20 | 15 | -32 | 37 | 0 |
| 30 Sep 20 | 14 | -21 | 26 | 0 |
| 30 Jun 20 | 14 | -19 | 25 | 0 |
| 31 Mar 20 | 14 | -18 | 25 | 0 |
| 31 Dec 19 | 14 | -17 | 24 | 0 |
| 30 Sep 19 | 12 | -16 | 22 | 0 |
| 30 Jun 19 | 11 | -18 | 22 | 0 |
| 31 Mar 19 | 9 | -18 | 21 | 0 |
| 31 Dec 18 | 9 | -17 | 20 | 0 |
| 30 Sep 18 | 9 | -14 | 19 | 0 |
| 30 Jun 18 | 9 | -13 | 18 | 0 |
| 31 Mar 18 | 8 | -12 | 17 | 0 |
| 31 Dec 17 | 10 | -10 | 16 | 0 |
| 30 Sep 17 | 13 | -15 | 23 | 0 |
| 31 Dec 16 | 7 | -13 | 16 | 0 |
Quality Earnings: EXPRS2 is currently unprofitable.
Growing Profit Margin: EXPRS2 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EXPRS2 is unprofitable, and losses have increased over the past 5 years at a rate of 44.9% per year.
Accelerating Growth: Unable to compare EXPRS2's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EXPRS2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: EXPRS2 has a negative Return on Equity (-157.55%), as it is currently unprofitable.